Condition: Multiple Primary Lung Cancer · Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Prospective, multi-center, phase II clinical trial. The study plans to enroll 146 patients with multiple lung cancers. After signing the informed consent, they were screened to meet the admission and discharge criteria, and received microwave ablation treatment. Electromagnetic navigation bronchoscope-guided intrapulmonary microwave ablation or percutaneous microwave ablation was selected according to the patient's wishes and the evaluation of the surgeon. After the operation, they were randomized and the experimental group accepted PD-1 immune checkpoint inhibitor treatment (microwave ablation combined with Camrelizumab treatment does not exceed 16 cycles, or disease progression/worsening or confirmed imaging disease progression, or withdrawal for any reason), the control group does not After receiving any treatment, the two groups were followed up closely (36 months after the last treatment, including safety follow-up and survival follow-up).
This description comes directly from the study's public registry record.
Chang Chen, Dr · 65115006 · 2031222@tongji.edu.cn
Always discuss trial participation with your own doctor first.
| Changhai Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai First People's Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Ruijin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Tenth People's Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Renji Hospital | Shanghai, Shangh, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05053802